Early C-reactive protein kinetics predicts immunotherapy response in non-small cell lung cancer in the phase III OAK trial.
JNCI cancer spectrum
View this publicationJNCI cancer spectrum
View this publicationPathogens (Basel, Switzerland)
View this publicationHuman brain mapping
View this publicationAlzheimer's research & therapy
View this publicationBlood advances
View this publicationScientific reports
View this publicationLeukemia
View this publicationThe New England journal of medicine
View this publicationInvestigative radiology
View this publicationThe Journal of allergy and clinical immunology
View this publication